Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study

YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study RESEARCH ARTICLE YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study Anne Roslind, MD,* Julia S. Johansen, MD, DMSc,w Nanna Junker, PhD,z Dorte L. Nielsen, MD, PhD, DMSc,* Hanife Dzaferi,y Paul A. Price, PhD,J and Eva Balslev, MDy KL-40 is a new biomarker with a potential prognostic Abstract: Elevated serum levels of the protein YKL-40 are Yvalue in cancer. In patients with localized and 2,3 4 associated with a poor prognosis in patients with solid and metastatic cancers including breast, colorectal, ovar- 5–7 8 9 10 11 hematologic malignancies including breast cancer. The aim of ian, small cell lung, renal, prostate, gliomas, 12,13 this study was to develop a valid reproducible immunohisto- malignant melanoma, and acute myeloid leukemia chemical method to visualize YKL-40 expression in normal an elevated serum level of YKL-40 is an independent breast tissue as well as in benign and malignant breast lesions. biomarker of poor prognosis. The presence of YKL-40 in breast tissue was verified by in situ In breast cancer, serum YKL-40 is elevated in 19% hybridization and protein extraction procedures. An immuno- and in 30% of patients with localized and metastatic histochemical method was developed and 4 different antibodies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study

Loading next page...
 
/lp/wolters-kluwer-health/ykl-40-expression-in-benign-and-malignant-lesions-of-the-breast-colon-glrLVvk1pn

References (57)

ISSN
1541-2016
DOI
10.1097/01.pai.0000213146.77772.6a
pmid
18091378
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE YKL-40 Expression in Benign and Malignant Lesions of the Breast: A Methodologic Study Anne Roslind, MD,* Julia S. Johansen, MD, DMSc,w Nanna Junker, PhD,z Dorte L. Nielsen, MD, PhD, DMSc,* Hanife Dzaferi,y Paul A. Price, PhD,J and Eva Balslev, MDy KL-40 is a new biomarker with a potential prognostic Abstract: Elevated serum levels of the protein YKL-40 are Yvalue in cancer. In patients with localized and 2,3 4 associated with a poor prognosis in patients with solid and metastatic cancers including breast, colorectal, ovar- 5–7 8 9 10 11 hematologic malignancies including breast cancer. The aim of ian, small cell lung, renal, prostate, gliomas, 12,13 this study was to develop a valid reproducible immunohisto- malignant melanoma, and acute myeloid leukemia chemical method to visualize YKL-40 expression in normal an elevated serum level of YKL-40 is an independent breast tissue as well as in benign and malignant breast lesions. biomarker of poor prognosis. The presence of YKL-40 in breast tissue was verified by in situ In breast cancer, serum YKL-40 is elevated in 19% hybridization and protein extraction procedures. An immuno- and in 30% of patients with localized and metastatic histochemical method was developed and 4 different antibodies

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Dec 1, 2007

There are no references for this article.